Israel -
hebraisk -
Ministry of Health
סטרטרה 10 מג
eli lilly israel ltd, israel - atomoxetine as hydrochloride - קפסולה קשיחה - atomoxetine as hydrochloride 10 mg - atomoxetine
Israel -
hebraisk -
Ministry of Health
סטרטרה 100 מג
eli lilly israel ltd, israel - atomoxetine as hydrochloride - קפסולה קשיחה - atomoxetine as hydrochloride 100 mg - atomoxetine
Israel -
hebraisk -
Ministry of Health
סטרטרה 18 מג
eli lilly israel ltd, israel - atomoxetine as hydrochloride - קפסולה קשיחה - atomoxetine as hydrochloride 18 mg - atomoxetine
Israel -
hebraisk -
Ministry of Health
סטרטרה 25 מג
eli lilly israel ltd, israel - atomoxetine as hydrochloride - קפסולה קשיחה - atomoxetine as hydrochloride 25 mg - atomoxetine
Israel -
hebraisk -
Ministry of Health
סטרטרה 40 מג
eli lilly israel ltd, israel - atomoxetine as hydrochloride - קפסולה קשיחה - atomoxetine as hydrochloride 40 mg - atomoxetine
Israel -
hebraisk -
Ministry of Health
סטרטרה 60 מג
eli lilly israel ltd, israel - atomoxetine as hydrochloride - קפסולה קשיחה - atomoxetine as hydrochloride 60 mg - atomoxetine
Israel -
hebraisk -
Ministry of Health
סטרטרה 80 מג
eli lilly israel ltd, israel - atomoxetine as hydrochloride - קפסולה קשיחה - atomoxetine as hydrochloride 80 mg - atomoxetine
Israel -
hebraisk -
Ministry of Health
לוסנטיס
novartis israel ltd - ranibizumab - תמיסה להזרקה - ranibizumab 10 mg/ml - ranibizumab - ranibizumab - treatment of patients with neovascular (wet) age-related macular degeneration (amd).treatment of adult patients with visual impairment due to diabetic macular oedema (dme) .the treatment of visual impairement due to macular oedema secondary to retinal vein occulsion (rvo).the treatment of visual impaiment due to choroidal neovacularization (cnv) secondary to pathologic myopia (pm).
Israel -
hebraisk -
Ministry of Health
אייליה
bayer israel ltd - aflibercept - תמיסה להזרקה לזגוגית העין - aflibercept 40 mg/ml - aflibercept
Israel -
hebraisk -
Ministry of Health
רבלימיד 5 מג
neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 5 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.